<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1817-5996</journal-id>
<journal-title><![CDATA[Revista Cubana de Reumatología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cuba Reumatol]]></abbrev-journal-title>
<issn>1817-5996</issn>
<publisher>
<publisher-name><![CDATA[Editorial CIMEQ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1817-59962020000300014</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Síndrome antifosfolipídico, lupus eritematoso sistémico y tromboembolismo pulmonar]]></article-title>
<article-title xml:lang="en"><![CDATA[Antiphospholipid syndrome, systemic lupus erythematosus and pulmonary thromboembolism. Case presentation]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Milián Hernández]]></surname>
<given-names><![CDATA[Eduardo Josué]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Betancourt Castellanos]]></surname>
<given-names><![CDATA[Liset]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Daza Coello]]></surname>
<given-names><![CDATA[Karla Michelle]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Técnica de Manabí  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>22</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1817-59962020000300014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1817-59962020000300014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1817-59962020000300014&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El síndrome antifosfolipídico o de Hughes, como también se le conoce, puede aparecer de manera aislada o asociado a otras enfermedades autoinmunes como el lupus eritematoso sistémico. La asociación de ambas entidades puede causar varias complicaciones, como el tromboembolismo pulmonar. Se presenta el caso de una paciente de 28 años de edad, con antecedentes de abortos a repetición y óbito fetal, ingresada en esta ocasión, debido a una trombosis venosa profunda del miembro superior derecho, confirmada mediante ecografía Doppler. Se comprobó el diagnóstico de síndrome antifosfolipídico secundario a lupus eritematoso sistémico, sustentado por los elementos clínicos e inmunitarios presentes. La paciente evolucionó satisfactoriamente, con el protocolo terapéutico empleado en fase aguda: heparina de bajo peso molecular del tipo clexane (enoxaparina) 1 mg/kg cada 12 h y dicumarínicos del tipo warfarina 5 mg con una razón normalizada internacional (INR) de 3. Se mantiene actualmente con una dosis de 10 mg/día e hidroxicloroquina 200 mg diarios.  Conclusiones:  Se resalta la importancia de diagnosticar el síndrome antifosfolipídico, ante toda paciente con abortos espontáneos o muertes perinatales inexplicables. El tratamiento debe ser multidisciplinario y se debe realizar una búsqueda sistemática de afecciones secundarias (particularmente enfermedades difusas del tejido conectivo) antes de calificar al síndrome como primario.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT The antiphospholipid or Hughes syndrome, as it is also known, can appear in isolation or in association with other autoimmune diseases such as systemic lupus erythematosus. The association of both entities can cause various complications, such as pulmonary thromboembolism. We present the case of a 28-year-old patient, with a history of repeated abortions and stillbirth, admitted on this occasion due to deep vein thrombosis of the right upper limb, confirmed by Doppler ultrasound. The diagnosis of antiphospholipid syndrome secondary to systemic lupus erythematosus was confirmed, supported by the clinical and immune elements present. The patient evolved satisfactorily, with the therapeutic protocol used in the acute phase, where she initially received treatment with low molecular weight heparin of the type clexane (enoxaparin) 1 mg x kg every 12 hours, and discoumarin drugs of the warfarin type, which she currently maintains at a 5mg dose with an INR of 3. Initially prednisone was placed at a dose of 1mg x kg with good therapeutic response, currently maintaining a 10mg dose. He is also currently on hydroxychloroquine 200 mg daily.  Conclusions:  The importance of diagnosing the antiphospholipid syndrome is highlighted in all patients with spontaneous abortions or unexplained perinatal deaths. Treatment should be multidisciplinary and a systematic search for secondary conditions (particularly diffuse connective tissue diseases) should be conducted before qualifying the syndrome as primary.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[síndrome antifosfolipídico]]></kwd>
<kwd lng="es"><![CDATA[lupus eritematoso sistémico]]></kwd>
<kwd lng="es"><![CDATA[tromboembolismo pulmonar]]></kwd>
<kwd lng="es"><![CDATA[abortos a repetición]]></kwd>
<kwd lng="es"><![CDATA[muerte fetal]]></kwd>
<kwd lng="en"><![CDATA[antiphospholipid syndrome]]></kwd>
<kwd lng="en"><![CDATA[systemic lupus erythematosus]]></kwd>
<kwd lng="en"><![CDATA[pulmonary thromboembolism]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Branch]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Rauch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Antiphospholipid Syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2002</year>
<volume>346</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>752-63</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[GRV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thrombosis, abortion, cerebral disease and lupus anticoagulant]]></article-title>
<source><![CDATA[Br Med J (Clin Res Ed)]]></source>
<year>1983</year>
<volume>287</volume>
<page-range>1088-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vásquez-Álvarez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Azañero-Haro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez-Casaverde]]></surname>
<given-names><![CDATA[IS]]></given-names>
</name>
<name>
<surname><![CDATA[Soto-Tarazona]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tromboembolismo pulmonar bilateral como presentación de un síndrome antifosfolipídico: un reporte de caso]]></article-title>
<source><![CDATA[Acta Med Perú]]></source>
<year>2018</year>
<volume>35</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>239-43</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sierra-Merlano]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha-Reyes]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno-Grau]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome antifosfolípido catastrófico (síndrome de Asherson) Presentación de un caso probable]]></article-title>
<source><![CDATA[Rev Cienc Biomed]]></source>
<year>2016</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>112-6</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Pedrera]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Aguirre-Zamorano]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Sánchez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mecanismos de aterosclerosis y enfermedad cardiovascular en el síndrome antifosfolípido y el lupus eritematoso sistémico. Alternativas terapéuticas]]></article-title>
<source><![CDATA[Med Clínica]]></source>
<year>2017</year>
<volume>149</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>160-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maioli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Calabrese]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Capsoni]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gerosa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Meroni]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Chighizola]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lung Disease in Antiphospholipid Syndrome]]></article-title>
<source><![CDATA[Semin Respir Crit Care Med]]></source>
<year>2019</year>
<volume>40</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>278-94</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cáliz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz del Campo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Galindo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Santamaría]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recomendaciones de la Sociedad Española de Reumatología sobre síndrome antifosfolípido primario. Parte I: Diagnóstico, evaluación y tratamiento]]></article-title>
<source><![CDATA[Reumatol Clínica]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valverde]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Santalla]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lupus eritematoso sistémico y síndrome antifosfolipídico: fertilidad y complicaciones obstétricas y fetales de la gestación]]></article-title>
<source><![CDATA[Clínica Investig Ginecol Obstet]]></source>
<year>2009</year>
<volume>36</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>161-92</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barreno-Roch]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Ángel-Arand]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz-Gaytán]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Aceves-Sanchezborja]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Guzmán-Silahua]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rubio-Jurad]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome antifosfolípidos, nociones generales]]></article-title>
<source><![CDATA[El Residente]]></source>
<year>2018</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>98-103</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Del Carpio-Orantes]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Deficiencia de factores de la coagulación IX, XI, XII y lupus eritematoso sistémico]]></article-title>
<source><![CDATA[Rev Hematol Mex]]></source>
<year>2019</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>137-41</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parchand]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Vijitha]]></surname>
<given-names><![CDATA[VS]]></given-names>
</name>
<name>
<surname><![CDATA[Misra]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combined central retinal artery and vein occlusion in lupus]]></article-title>
<source><![CDATA[BMJ Case Reports]]></source>
<year>2017</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Rayón]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oclusión mixta de arteria y vena central de la retina; primera manifestación de lupus en paciente pediátrico]]></article-title>
<source><![CDATA[Arch Soc Esp Oftalmol]]></source>
<year>2019</year>
<volume>94</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>141-4</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Restrepo]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Velásquez]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz-Grajales]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pinto]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Márquez]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of factor Xa inhibitors in antiphospholipid antibodies syndrome: A serie of 7 cases]]></article-title>
<source><![CDATA[Rev Colomb Reumatol]]></source>
<year>2018</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>16-21</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camarena]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Jaimes]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Acevedo-Gallegos]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gallardo-Gaona]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Velázquez-Torres]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Calvo]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Controversias del síndrome de anticuerpos antifosfolipídicos en obstetricia]]></article-title>
<source><![CDATA[Reumatol Clínica]]></source>
<year>2017</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>30-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mieres]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rivero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Elizondo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Facal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome de Budd-Chiari asociado a síndrome antifosfolípido]]></article-title>
<source><![CDATA[Rev Med Urug]]></source>
<year>2019</year>
<volume>35</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>60-6</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ayala]]></surname>
<given-names><![CDATA[EN]]></given-names>
</name>
<name>
<surname><![CDATA[Charaja]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[IE]]></given-names>
</name>
<name>
<surname><![CDATA[Yupari]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Cornejo]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome de Evans en paciente con síndrome antifosfolipídico secundario: Desafío terapéutico]]></article-title>
<source><![CDATA[Rev Cuba Reumatol]]></source>
<year>2016</year>
<volume>18</volume>
<page-range>196-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bertolaccini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sanna]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent advances in understanding antiphospholipid syndrome]]></article-title>
<source><![CDATA[Version 1. F1000Research]]></source>
<year>2016</year>
<volume>5</volume>
<page-range>2908</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
